Lipoprime - Instructions For Use, Price, Reviews, Analogs Of Tablets

Lipoprime

Lipoprime: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation

1. 10. Use in childhood
2. 11. In case of impaired renal function
3. 12. For violations of liver function
4. 13. Drug interactions
5. 14. Analogs
6. 15. Terms and conditions of storage
7. 16. Terms of dispensing from pharmacies
8. 17. Reviews
9. 18. Price in pharmacies

Latin name: Lipoprime

ATX code: C10AA07

Active ingredient: rosuvastatin (Rosuvastatin)

Manufacturer: Micro Labs, Limited (India)

Description and photo updated: 30.11.2018

Prices in pharmacies: from 138 rubles.

Buy

Lipoprime is a lipid-lowering drug.

Release form and composition

Dosage form - film-coated tablets: round biconvex, white or almost white core color; dosage 5 mg - yellow shell, engraved ML on one side; dosage of 10 mg - light pink shell, MICRO engraving on one side; dosage 20 mg - orange shell, MICRO engraving on one side (in a cardboard box 3 blisters of 10 tablets and instructions for use of Lipoprime).

Composition of 1 tablet:

• active substance: rosuvastatin - 5, 10 or 20 mg (rosuvastatin calcium - 5.762; 11.524 or 23.048 mg);
• auxiliary components (5/10/20 mg): crospovidone (type B) - 0.75 / 1.5 / 3 mg; calcium phosphate - 5/10/20 mg; microcrystalline cellulose - 32.988 / 65.976 / 131.952 mg; magnesium stearate -1.5 / 3/6 mg; lactose monohydrate - 34/68/136 mg;
• Instacoat universal shell (yellow / pink / orange): (titanium dioxide - 0.32 / 0.79 / 1.37 mg; macrogol - 0.26 / 0.52 / 1.04 mg; hypromellose - 1.3 / 2, 6 / 5.2 mg; talc - 0.04 / 0.08 / 0.16 mg; quinoline yellow dye - 0.084 / - / - mg; sunset yellow dye: - / - / 0.23 mg; red dye iron oxide: - / 0.01 / - mg) - 2/4/8 mg.

Pharmacological properties

Pharmacodynamics

Rosuvastatin is one of the selective, competitive inhibitors of HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase. It is an enzyme that converts HMG-CoA to mevalonate, which is a precursor to cholesterol. The main target of rosuvastatin action is the liver. In this organ, the synthesis of cholesterol (cholesterol) and the catabolism of LDL (low density lipoproteins) are carried out.

The substance increases the number of hepatic LDL receptors located on the cell surface (due to an increase in the uptake and catabolism of LDL). In turn, this leads to inhibition of the synthesis of VLDL (very low density lipoproteins) and a decrease in the total number of LDL and VLDL.

Against the background of the use of rosuvastatin, there is a decrease in the increased concentration of total cholesterol, LDL-C (LDL cholesterol), TG (triglycerides), an increase in the concentration of HDL-C (high density lipoprotein cholesterol). In addition, the following effects are observed:

• decrease in the concentration of ApoB (apolipoprotein B), cholesterol-VLDL, cholesterol-non-HDL, TG-VLDL;
• an increase in the level of ApoA-I (apolipoprotein AI),
• decrease in the ratios: cholesterol-LDL / cholesterol-HDL, cholesterol-non-HDL / cholesterol-HDL, total cholesterol / cholesterol-HDL, apoV / apoA-1.

The development of the therapeutic effect is manifested within 7 days after the start of taking rosuvastatin, after 14 days, values close to the maximum (about 90%) are achieved. The maximum therapeutic effect usually develops by the fourth week, with regular use of Lipoprime, it is further maintained.

The use of rosuvastatin is effective in adult patients with hypercholesterolemia with / without hypertriglyceridemia. Race, gender or age, as well as the presence of diabetes mellitus and familial hypercholesterolemia, does not affect the effectiveness of Lipoprim.

With hypercholesterolemia of type IIa and IIb according to Fredrickson's classification (in patients with an average initial concentration of LDL-C of about 4.8 mmol / L) while taking 10 mg of rosuvastatin in 80% of cases, the concentration of LDL-C decreases to> 3 mmol / L.

With heterozygous familial hypercholesterolemia in patients receiving from 20 to 80 mg rosuvastatin, there is a change in the dynamics of lipid profile indicators to positive. After titration to a dose of 40 mg per day (at the 12th week of therapy), a decrease in the concentration of LDL-C by 53% is noted.

On average, the decrease in the concentration of LDL-C in patients with homozygous familial hypercholesterolemia, receiving therapy with rosuvastatin at a dose of 20 and 40 mg, is 22%.

When used in combination with fenofibrate, an additive effect is observed, aimed at the concentration of triglycerides; with nicotinic acid (in lipid-lowering doses - from 1000 mg per day) - on the concentration of HDL-C.

Pharmacokinetics

C _max (maximum concentration) of rosuvastatin in blood plasma is reached approximately 5 hours after oral administration of the drug. The absolute bioavailability is about 20%. The metabolism of rosuvastatin occurs mainly in the liver - the main site of the synthesis of cholesterol and the metabolism of cholesterol-LDL. V _d (volume of distribution) of rosuvastatin - approximately 134 liters. About 90% of the substance binds to blood plasma proteins, mainly albumin.

Rosuvastatin undergoes limited metabolism (approximately 10% of the dose). The substance belongs to non-core substrates for metabolism by isoenzymes of the cytochrome P _{450 system}. The main isoenzyme involved in metabolism is the CYP2C9 isoenzyme. To a lesser extent, isoenzymes CYP2C19, CYP3A4 and CYP2D6 are involved in metabolism.

Lactone metabolites and N-desmethyl are the main identified metabolites of rosuvastatin. N-desmethylrosuvastatin is approximately 50% less active than the parent substance; lactone metabolites have no pharmacological activity. Most (from 90%) of the pharmacological activity to inhibit circulating HMG-CoA reductase is directly associated with rosuvastatin, the rest is provided by metabolites.

Approximately 90% of the dose of rosuvastatin is excreted unchanged through the intestine (including absorbed and non-absorbed substance). The remaining part is excreted by the kidneys. Plasma T _1/2 (half-life) is about 19 hours. With an increase in the dose of Lipoprim, the T _1/2 value does not change. The geometric mean plasma clearance is approximately 50 l / h (coefficient of variation is 21.7%). In the process of hepatic uptake of rosuvastatin, as in the case of other inhibitors of HMG-CoA reductase, the membrane transporter of cholesterol is involved, which plays an important role in the hepatic elimination of rosuvastatin.

The systemic exposure of rosuvastatin is linear and increases in proportion to the dose. The pharmacokinetic parameters of the substance do not change with daily intake.

Compared to Europeans, pharmacokinetic studies have shown an approximately twofold increase in the median AUC (area under the concentration-time curve) and C _{max of} rosuvastatin in blood plasma in patients of Asian ethnicity (including Filipinos, Japanese, Chinese, Koreans and Vietnamese); in Indian patients, AUC and C _max increases 1.3 times. Differences in pharmacokinetics among Europeans and representatives of the Negroid race, which are of clinical importance, were not identified during the pharmacokinetic analysis.

The value of the plasma concentration of rosuvastatin or N-desmethylrosuvastatin in mild to moderate renal failure does not change significantly. Against the background of severe renal failure in patients with CC (creatinine clearance) of less than 30 ml / min, the plasma concentration of rosuvastatin in the blood is 3 times higher, and the concentration of N-desmethylrosuvastatin is 9 times higher than that in healthy volunteers. In patients on hemodialysis, the plasma concentration of rosuvastatin in the blood exceeds that in healthy volunteers by approximately 50%.

In liver failure, two patients with scores 8 and 9 on the Child-Pugh scale showed an increase in T _{1/2 by} at least 2 times. In patients with a score of 7 and below, no change in this indicator was found. In patients with 9 points and above, rosuvastatin was not used.

Rosuvastatin, like other inhibitors of HMG-CoA reductase, binds to transport proteins OATP1B1 (which are polypeptides for the transport of organic anions involved in the capture of statins by hepatocytes) and BCRP (refers to efflux transporter proteins). In carriers of genotypes SLC01B1 (OATP1B1) С.521СС and ABCG2 (BCRP) С.421АА, there was an increase in exposure (AUC) to rosuvastatin by 1.6 and 2.4 times, respectively, compared with carriers of genes SLC01B1 c.52ITT and ABCG2 С.421СС …

Indications for use

• primary hypercholesterolemia (type IIa according to the Fredrickson classification, including familial heterozygous hypercholesterolemia) or mixed type of hypercholesterolemia (type IIb): Lipoprime is prescribed as an addition to the diet of patients in whom diet and other non-drug therapies (such as weight loss, exercise) are not effective enough;
• familial homozygous hypercholesterolemia: Lipoprime is prescribed as an adjunct to diet and other methods of lipid-lowering therapy (for example, LDL apheresis), or in patients in whom such treatment has insufficient therapeutic effect;
• hypertriglyceridemia (type IV according to the Fredrickson classification): Lipoprime is prescribed as an addition to the diet;
• atherosclerosis: Lipoprime is indicated as an addition to the diet in order to slow the progression of the disease in patients who are recommended treatment to reduce the concentration of total cholesterol and LDL-C;
• main cardiovascular complications: Lipoprime is prescribed as the primary prevention of the development of arterial revascularization, stroke, heart attack in adult patients who do not have clinical signs of coronary heart disease, but with an increased risk of its development, including the age of 50 years for men and 60 years for women, an increased concentration of C-reactive protein (≥ 2 mg / L), and at least one additional risk factor - arterial hypertension, low concentration of HDL-C, smoking, family history of early onset of coronary heart disease.

Contraindications

The daily dose of rosuvastatin 5, 10 and 20 mg

Absolute:

• severe impairment of renal function (in patients with CC less than 30 ml / min);
• liver disease in the active phase (patients with a persistent increase in serum transaminase activity and any increase in serum transaminase activity more than 3 times in comparison with the upper limit of the norm);
• the presence of a predisposition to the development of myotoxic complications;
• myopathy;
• lactose intolerance, glucose-galactose malabsorption or lactase deficiency;
• simultaneous use with cyclosporine;
• lack of adequate contraception in women of childbearing age;
• pregnancy, lactation period;
• age up to 18 years;
• individual intolerance to the components of the drug.

Relative (Lipoprime is prescribed under medical supervision):

• the presence of risk factors for the development of myopathy / rhabdomyolysis, including renal failure, aggravated personal / family history of muscle diseases, hypothyroidism, aggravated history of myotoxicity during therapy with other HMG-CoA reductase inhibitors or fibrates;
• conditions in which an increase in the plasma concentration of rosuvastatin is possible;
• a history of liver disease;
• sepsis;
• arterial hypotension;
• severe metabolic, water-electrolyte, or endocrine disorders, or uncontrolled seizures;
• trauma, major surgical interventions;
• excessive alcohol consumption;
• simultaneous use with fibrates;
• belonging to the Asian race;
• age from 65 years.

The daily dose of rosuvastatin 40 mg

• liver disease in the active phase (patients with a persistent increase in serum transaminase activity and any increase in serum transaminase activity more than 3 times in comparison with the upper limit of the norm);
• the presence of risk factors for the development of myopathy / rhabdomyolysis, including moderate renal failure (in patients with CC less than 60 ml / min), a personal / family history of muscle diseases, hypothyroidism, a history of myotoxicity during therapy with other HMG-CoA reductase inhibitors or fibrates;
• liver failure;
• excessive alcohol consumption;
• conditions in which an increase in the plasma concentration of rosuvastatin is possible;
• lactose intolerance, glucose-galactose malabsorption or lactase deficiency;
• simultaneous use with cyclosporine and fibrates;
• belonging to the Asian race;
• age up to 18 years;
• lack of adequate contraception in women of childbearing age;
• pregnancy, lactation period;
• individual intolerance to the components of the drug.

Relative (Lipoprime tablets are prescribed under medical supervision):

• renal failure of mild severity (in patients with CC more than 60 ml / min);
• a history of liver disease;
• sepsis;
• arterial hypotension;
• trauma, major surgical interventions;
• severe metabolic, fluid and electrolyte / endocrine disturbances or uncontrolled seizures;
• age from 65 years.

Lipoprime, instructions for use: method and dosage

Lipoprime tablets are taken orally: swallowed whole without chewing and drinking water, regardless of food intake and time of day.

Before taking the drug, you need to start observing the standard hypocholesterolemic diet, which is not canceled in the future.

The dosage regimen is determined individually. It depends on the goals of treatment and the clinical response to the ongoing therapy, taking into account the current recommendations for the target lipid concentration.

When choosing the initial dose of Lipoprim, they are guided by the individual concentration of cholesterol, be sure to take into account the risk of cardiovascular complications and the potential for side effects.

Initiate therapy, including in patients who are transferred from other HMG-CoA reductase inhibitors, with 5 or 10 mg once a day. After 4 weeks, the dose may be increased if necessary.

In comparison with lower doses, with the use of 40 mg of Lipoprim, the risk of side effects increases. Therefore, an increase in the dose to the maximum (40 mg) is possible only with a severe degree of hypercholesterolemia and a high risk of cardiovascular complications (especially in patients with familial hypercholesterolemia), in whom the desired result of therapy with a dose of 20 mg was not achieved. Their condition must be monitored. The appointment of the maximum dose for patients who see a doctor for the first time is not recommended.

After the end of 2–4 weeks of therapy and / or with an increase in the dose of Lipoprim, monitoring of lipid metabolism is required (the dose can be adjusted).

The recommended starting dose for patients with moderate renal impairment is 5 mg.

For patients of the Asian race, as well as patients with a predisposition to myopathy, the recommended initial dose for the appointment of therapeutic doses of 10 and 20 mg is 5 mg. The maximum dose for this group of patients is not prescribed.

For patients who are carriers of the C.521CC or C.421AA genotypes, the recommended maximum daily dose of Lipoprim is 20 mg.

When Lipoprime is combined with individual drugs (for example, with cyclosporine, some HIV protease inhibitors, including the combination of ritonavir with lopinavir, atazanavir and / or tipranavir), which lead to an increase in the plasma concentration of rosuvastatin in the blood due to interaction with transport proteins, it may increase risk of myopathy (including rhabdomyolysis).

Before starting the combination therapy, the doctor should evaluate the possibility of prescribing an alternative treatment or temporary discontinuation of Lipoprime. If the use of the above drugs is necessary, you need to balance the benefits and risks and consider the possibility of reducing the dose.

Side effects

Against the background of rosuvastatin therapy, side effects are usually mild and do not require additional treatment. The frequency of development of disorders depends on the dose used.

Possible adverse reactions (> 10% - very common;> 1% and 0.1% and 0.01% and <0.1% - rarely; <0.01% - very rare):

• endocrine system: often - type 2 diabetes mellitus;
• immune system: rarely - hypersensitivity reactions, including angioedema;
• digestive system: often - constipation, nausea, abdominal pain; rarely - pancreatitis;
• nervous system: often - dizziness, headache;
• skin: infrequently - rash, skin itching, urticaria;
• urinary system: proteinuria (usually decreases / disappears in the process of continuing therapy; the development of acute or progression of existing kidney disease does not mean);
• musculoskeletal system: often - myalgia; rarely - myopathy (including myositis), rhabdomyolysis;
• liver: increased activity of hepatic transaminases (occurs in a small number of patients; usually this disorder is asymptomatic, insignificant and temporary; is dose-dependent);
• laboratory parameters: increased bilirubin, alkaline phosphatase, glucose concentration, gamma-glutamyl transpeptidase activity, thyroid dysfunction;
• others: often - asthenic syndrome.

There is also information about the development of adverse reactions recorded during post-marketing surveillance:

• digestive system: rarely - increased activity of hepatic transaminases; very rarely - hepatitis, jaundice; with an unknown frequency - diarrhea;
• hematopoietic system: with an unknown frequency - thrombocytopenia;
• reproductive system: very rarely - gynecomastia;
• respiratory system: with an unknown frequency - shortness of breath, cough;
• urinary system: very rarely - hematuria;
• nervous system: very rarely - decrease / loss of memory; with an unspecified frequency - peripheral neuropathy;
• musculoskeletal system: very rarely - arthralgia; with an unknown frequency - immune-mediated necrotizing myopathy;
• skin: with an unknown frequency - Stevens-Johnson syndrome;
• others: with an unknown frequency - peripheral edema.

During therapy with some statins, the following side effects were reported: hyperglycemia, sexual dysfunction, depression, an increase in the concentration of glycated hemoglobin, sleep disturbances (including insomnia and nightmares). There is information about isolated cases of interstitial lung disease, especially with long-term treatment.

Overdose

The main symptoms: the pharmacokinetic parameters of rosuvastatin do not change in the case of simultaneous administration of several daily doses of Lipoprime.

Therapy: symptomatic; carrying out activities aimed at maintaining the functions of vital organs and systems. Patients require monitoring of liver function and creatine phosphokinase activity.

There is no specific therapy for overdose with rosuvastatin. Hemodialysis is most likely ineffective.

special instructions

When Lipoprime was taken in a daily dose of 40 mg, some patients developed tubular proteinuria, which was most often of a transient nature. This disorder does not indicate acute kidney disease or progression of kidney disease. During therapy with high doses of rosuvastatin, monitoring of renal function indicators is recommended.

In the course of therapy, mainly in patients taking rosuvastatin in a daily dose of 20 mg or more, the following disorders of the musculoskeletal system may develop: myopathy, myalgia, in rare cases - rhabdomyolysis.

Determination of creatine phosphokinase after intense physical exertion or in the presence of other possible reasons for an increase in its activity should not be carried out, since this may lead to an incorrect interpretation of the results obtained. If the initial value of this indicator is significantly increased (5 times higher than the upper limit of the norm), a second measurement should be carried out after 5-7 days. With a secondary confirmation of an increased value, Lipoprim therapy should not be started.

In the case of prescribing the drug to patients with risk factors for the development of myopathy / rhabdomyolysis, it is necessary to assess the ratio of benefit and existing risk. During treatment, the condition of such patients should be monitored.

If you suddenly develop muscle pain, weakness, or spasms, especially in combination with fever and malaise, you should see your doctor. In these cases, the determination of the activity of creatine phosphokinase is shown. If this indicator is significantly exceeded from the norm (more than 5 times) or in the presence of pronounced muscle pain that causes daily discomfort, Lipoprime is canceled. After the symptoms disappear and the creatine phosphokinase value normalizes, the doctor may re-prescribe therapy with Lipoprime or another HMG-CoA reductase inhibitor in a lower daily dose, subject to careful monitoring of the condition.

Routine monitoring of creatine phosphokinase activity in asymptomatic patients is impractical. There is information about rare cases of the development of immune-mediated necrotizing myopathy, accompanied by such clinical manifestations as an increase in serum creatine phosphokinase activity and weakness of the proximal muscles, during administration or during withdrawal of statins, including rosuvastatin. Such patients may be assigned additional studies of the nervous and muscular system, serological studies, as well as the use of immunosuppressive drugs.

When taking rosuvastatin drugs and concomitant therapy, there were no signs of an increase in the effect on skeletal muscle. However, there are reports of an increase in the number of cases of myopathy and myositis in patients who took other HMG-CoA reductase inhibitors concurrently with fibric acid derivatives, including drugs such as cyclosporine, HIV protease inhibitors, gemfibrozil, nicotinic acid in lipid-lowering doses (from 1000 mg per day), macrolide antibiotics, azole antifungal agents.

When gemfibrozil is administered concurrently with some HMG-CoA reductase inhibitors, the likelihood of myopathy increases. In this regard, the combination therapy of rosuvastatin and gemfibrozil is not recommended. Before prescribing Lipoprim in combination with fibrates or nicotinic acid in lipid-lowering doses, an assessment of the benefit-to-risk ratio should be made. The simultaneous use of rosuvastatin in a daily dose of 40 mg and fibrates is contraindicated.

After 2-4 weeks after the start of therapy and / or with an increase in the dose of Lipoprime, it is necessary to monitor lipid metabolism (if necessary, dose adjustment is performed).

Before the start of therapy and at the end of three months of taking the drug, it is recommended to determine the indicators of hepatic function. In cases where the indicator of the activity of hepatic transaminases in the blood serum exceeds the upper limit of the norm by 3 times, the dose of Lipoprim should be reduced or its intake should be canceled.

In case of hypercholesterolemia associated with hypothyroidism or nephrotic syndrome, prior to taking Lipoprime, it is necessary to treat the underlying diseases.

Combination therapy with HIV protease inhibitors is not recommended.

At a glucose concentration of 5.6–6.9 mmol / L, the use of rosuvastatin is associated with an increased risk of type 2 diabetes mellitus.

Against the background of the use of some statins, mainly long-acting, the development of interstitial lung disease is possible (there is information about isolated cases). The main symptoms: deterioration in general health (in the form of weakness, weight loss, fever), unproductive cough, shortness of breath. If there is a suspicion of the development of interstitial lung disease, Lipoprime is canceled.

Influence on the ability to drive vehicles and complex mechanisms

Studies to study the effect of Lipoprime on the ability to drive vehicles have not been conducted. Patients during therapy should take into account the likelihood of developing dizziness and be careful.

Application during pregnancy and lactation

Lipoprime is not prescribed during pregnancy / lactation.

Women of reproductive age are advised to use adequate methods of contraception during therapy.

Cholesterol and other products of cholesterol biosynthesis play an important role for the development of the fetus, therefore, the potential risk of inhibition of HMG-CoA reductase is estimated higher than the benefits of using Lipoprim in pregnant women. When pregnancy occurs during therapy, immediate drug withdrawal is required.

There is no information on whether rosuvastatin is excreted in breast milk.

Pediatric use

The safety profile of Lipoprim in patients under 18 years of age has not been studied, and therefore the use of the drug in this group of patients is contraindicated.

With impaired renal function

Daily dose of 5, 10 and 20 mg:

• severe impairment of renal function (in patients with CC less than 30 ml / min): therapy is contraindicated;
• renal failure: Lipoprime is prescribed with caution.

Daily dose 40 mg:

• severe and moderate renal failure (in patients with CC less than 60 ml / min): therapy is contraindicated;
• mild renal failure (in patients with CC more than 60 ml / min): Lipoprim is prescribed with caution.

For violations of liver function

• liver disease in the active phase (patients with a persistent increase in serum transaminase activity and any increase in serum transaminase activity more than 3 times in comparison with the upper limit of the norm); additionally for a daily dose of 40 mg - liver failure: therapy is contraindicated;
• history of liver disease: Lipoprime is prescribed with caution.

There is no experience with Lipoprime in patients with a score above 9 on the Child-Pugh scale.

Drug interactions

• cyclosporine: AUC of rosuvastatin increases significantly (by about 7 times), the plasma concentration of cyclosporin does not change; combination therapy is contraindicated;
• gemfibrozil and other lipid-lowering drugs: C _max and AUC of rosuvastatin increase; pharmacokinetically significant interaction with fenofibrate is not expected, pharmacodynamic interaction is possible;
• fenofibrate, gemfibrozil, other fibrates and nicotinic acid in lipid-lowering doses (from 1000 mg per day): the risk of myopathy increases, which can lead to its development; when carrying out combination therapy, the initial dose of rosuvastatin should be 5 mg; the simultaneous use of fibrates and rosuvastatin at a dose of 40 mg is contraindicated;
• ezetimibe: due to pharmacodynamic interactions, an increase in the likelihood of adverse reactions cannot be ruled out;
• HIV protease inhibitors: the exposure of rosuvastatin is significantly increased (the mechanism of interaction has not been established); AUC and C _{max of} rosuvastatin increases; simultaneous use is not recommended;
• antacids: there is a significant decrease in the plasma concentration of rosuvastatin, the severity of this effect can be reduced by observing a 2 hour interval between taking drugs; the clinical significance of the interaction has not been studied;
• erythromycin: leads to a significant decrease in AUC and C _{max of} rosuvastatin (by 20 and 30%, respectively); the development of interaction is associated with an increase in intestinal motility caused by the use of erythromycin;
• fusidic acid: as in the case of taking other statins, there is information about the development of rhabdomyolysis (based on the results of post-marketing use); interaction studies have not been conducted, when prescribing combination therapy, observation of the patient's condition should be established, if necessary, Lipoprime can be temporarily canceled.

In the case of simultaneous use of Lipoprime with drugs that increase exposure to rosuvastatin, dose adjustment may be required. If the expected increase in exposure is 2 or more times, the initial daily dose of rosuvastatin should be 5 mg.

It is also necessary to adjust the maximum daily dose of Lipoprime so that the expected exposure to rosuvastatin is not higher than that for a dose of 40 mg taken as monotherapy. For example, with simultaneous use with atazanavir / ritonavir and gemfibrozil, the maximum daily dose of Lipoprime is 10 and 20 mg, respectively (the expected increase in exposure is 3.1 and 1.9 times).

Effect of rosuvastatin on other medicines:

• vitamin K antagonists: during the initiation of the use of rosuvastatin or with an increase in its dose, an increase in the INR (International Normalized Ratio) is possible; similarly, with the abolition of rosuvastatin or a decrease in its dose, the INR value may decrease; if it is necessary to carry out combination therapy, control of this indicator is required;
• oral contraceptives / hormone replacement therapy: there is an increase in the AUC of ethinyl estradiol and norgestrel by 26 and 34%, respectively, which should be taken into account when selecting their dose. This combination has been widely used in clinical trials and is generally well tolerated by patients.

Analogs

Lipoprime analogs are: Tevastor, Rosuvastatin, Crestor, Rosuvastatin-SZ, Rosulip, Roxera, Rosucard, Akorta, Mertenil, Rozistark, Reddistatin, Suvardio, Rosart, etc.

Terms and conditions of storage

Store at temperatures up to 25 ° C. Keep out of the reach of children.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Lipoprime

Reviews about Lipoprime are few. The cost of the drug is most often characterized as affordable. Patients rarely report the development of side effects.

Lipoprime price in pharmacies

Approximate price for Lipoprime per pack containing 30 tablets, depending on the dosage:

• tablets 5 mg - 287 rubles;
• tablets 10 mg - 322 rubles;
• tablets 20 mg - 355 rubles.

Lipoprime: prices in online pharmacies

Drug name Price Pharmacy

Lipoprime 5 mg film-coated tablets 30 pcs. RUB 138 Buy

Lipoprime tablets p.o. 5mg 30 pcs. 293 r Buy

Lipoprime 10 mg film-coated tablets 30 pcs. 333 r Buy

Lipoprime tablets p.o. 10mg 30 pcs. RUB 360 Buy

Lipoprime tablets p.p. 20mg 30 pcs. 431 r Buy

Lipoprime 20 mg film-coated tablets 30 pcs. 431 r Buy

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!